Novel Brentuximab Vedotin Combination Therapies Show Promising Activity in Highly Refractory CD30+ Non-Hodgkin Lymphoma: A Case Series and Review of the Literature

Case Reports in Oncological Medicine

Volumn 2016, Issue , 2016, Pages

  Delacruz, Wilfred ^a   Setlik, Robert ^a   Hassantoufighi, Arash ^a   Daya, Shyam ^a   Cooper, Susannah ^a   Selby, Dale ^a   Brown, Alexander ^a  

^a SAN ANTONIO MILITARY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ATOVAQUONE; BRENTUXIMAB VEDOTIN; CD30 ANTIGEN; CEFEPIME; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDROCORTISONE; FOLINIC ACID; LACTATE DEHYDROGENASE; LEVOFLOXACIN; MESNA; METHOTREXATE; METHYLPREDNISOLONE; PEGFILGRASTIM; POSACONAZOLE; PREDNISONE; RITUXIMAB; THIOTEPA; TOPOTECAN; URIC ACID; VINCRISTINE;

ABDUCENS NERVE PARALYSIS; ACUTE DIARRHEA; ACUTE KIDNEY FAILURE; ADRENAL INSUFFICIENCY; ADULT; ALTERNATIVE MEDICINE; ANEMIA; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; ARM WEAKNESS; ARTICLE; ARTIFICIAL VENTILATION; AUTONOMIC DYSFUNCTION; AXILLARY LYMPH NODE; BACTEREMIA; BLOOD SMEAR; BONE LESION; BONE MARROW BIOPSY; BRAIN DISEASE; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; CERVICAL LYMPHADENOPATHY; CHEMOSENSITIVITY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; CRANIAL NERVE PARALYSIS; CRANIAL NEUROPATHY; DECREASED APPETITE; DIAPHORESIS; DIARRHEA; DIPLOPIA; DIZZINESS; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPHAGIA; ELECTROCORTICOGRAPHY; EYELID DISEASE; FAINTNESS; FEBRILE NEUTROPENIA; FEMALE; FLOW CYTOMETRY; FOLLOW UP; FUNCTIONAL STATUS; HEADACHE; HOARSENESS; HOSPICE CARE; HUMAN; HYPONATREMIA; HYPOXIA; IMMUNOHISTOCHEMISTRY; INTENSIVE CARE UNIT; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; LYMPH NODE BIOPSY; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; MULTIPLE CYCLE TREATMENT; MULTIPLE PULMONARY NODULES; NAUSEA; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCYTOPENIA; PARANASAL SINUS DISEASE; PARIETAL LOBE; PERIPHERAL NEUROPATHY; PSEUDOMONAS INFECTION; RECURRENT LARYNGEAL NERVE PALSY; RESPIRATORY DISTRESS; SALVAGE THERAPY; SEPSIS; SPHENOID SINUS; THROMBOCYTOPENIA; URIC ACID BLOOD LEVEL; VERTIGO; WEIGHT REDUCTION;

EID: 85006965670     PISSN: 20906706     EISSN: 20906714     Source Type: Journal    
DOI: 10.1155/2016/2596423     Document Type: Article

References (30)

1. J. O. Armitage, "Treatment of non-Hodgkin's lymphoma, " The New England Journal ofMedicine, vol. 328, no. 14, pp. 1023-1030, 1993.
2. M. P. Chao, "Treatment challenges in the management of relapsed or refractory non-Hodgkin's lymphoma-novel and emerging therapies, " Cancer Management and Research, vol. 5, no. 1, pp. 251-269, 2013.
3. S. Alici, S. Bavbek, M. Basaran, andH. Onat, "Prognostic factors in patients with aggressive non-Hodgkin's lymphoma without complete response to first-line therapy, " Advances in Therapy, vol. 23, no. 4, pp. 534-542, 2006.
4. Seattle Genetics, I., Brentuximab Vendotin Package Insert.
5. S. M. Ansell, "Brentuximab vedotin, " Blood, vol. 124, no. 22, pp. 3197-3200, 2014.
6. E. D. Jacobsen, J. P. Sharman, Y. Oki et al., "Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression, " Blood, vol. 125, no. 9, pp. 1394-1402, 2015.
7. C. Saintes, M. Saint-Jean, J. J. Renaut, B. Dréno, andG. Quéreux, "Dramatic efficacy of brentuximab vedotin in two patients with epidermotropic cutaneous T-cell lymphomas after treatment failure despite variable CD30 expression, " British Journal of Dermatology, vol. 172, no. 3, pp. 819-821, 2015.
8. Y. H. Kim, M. Tavallaee, U. Sundram et al., "Phase II investigator-initiated study of brentuximab vedotin in mycosis fungoides and Sézary syndrome with variable CD30 expression level: A multi-institution collaborative project, " Journal of Clinical Oncology, vol. 33, no. 32, pp. 3750-3758, 2015.
9. W. Y. Kim, S. J. Nam, S. Kim et al., "Prognostic implications of CD30 expression in extranodal natural killer/T-cell lymphoma according to treatment modalities, " Leukemia and Lymphoma, vol. 56, no. 6, pp. 1778-1786, 2015.
10. A. Younes, A. K. Gopal, S. E. Smith et al., "Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma, " Journal of Clinical Oncology, vol. 30, no. 18, pp. 2183-2189, 2012.
11. C. H. Moskowitz, A. Nademanee, T. Masszi et al., "Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): A randomised, doubleblind, placebo-controlled, phase 3 trial, "TheLancet, vol. 385, no. 9980, pp. 1853-1862, 2015.
12. B. Pro, R. A. P. Brice, N. Bartlett et al., "Durable remissions with brentuximab vedotin (SGN-35): Updated results of a phase II study in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL), " Journal of Clinical Oncology, vol. 29, no. 15s, article 8032, 2011.
13. N. L. Bartlett, R. Chen, M. A. Fanale et al., "Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies, " Journal of Hematology and Oncology, vol. 7, no. 1, article 24, 2014.
14. R. Camicia, H. C. Winkler, and P. O. Hassa, "Novel drug targets for personalized precision medicine in relapsed/refractory diffuse largeB-cell lymphoma: A comprehensive review, "Molecular Cancer, vol. 14, no. 1, p. 207, 2015.
15. A. Younes, J. M. Connors, S. I. Park et al., "Brentuximab vedotin combined with ABVD or AVDfor patients with newly diagnosed Hodgkin's lymphoma: A phase 1, open-label, doseescalation study, " The Lancet Oncology, vol. 14, no. 13, pp. 1348-1356, 2013.
16. Millennium Pharmaceuticals, I., Phase 3 Frontline Therapy Trial in Patients With Advanced Classical Hodgkin Lymphoma NCT01712490.
17. M. A. Fanale, S. M. Horwitz, A. Forero-Torres et al., "Brentuximab vedotin administered before, during, and aftermulti-agent chemotherapy in patients (pts) with newly-diagnosed CD301 mature T-and NK-cell lymphomas, " Blood, vol. 122, no. 21, abstract 4386, 2013.
18. Seattle Genetics Inc, "ECHELON-2: A comparison of brentuximab vedotin and CHP with standard-of-care CHOP in the treatment of patients with CD30-positive mature Tcell lymphomas (ECHELON-2), " https://clinicaltrials. gov/ct2/ show/NCT01777152.
19. U. S. Food and Drug Administration, U. S. Food and Drug Administration: 'Off-Label' and Investigational Use of Marketed Drugs, Biologics, andMedical Devices-Information Sheet Updated, http://www. fda. gov/RegulatoryInformation/ Guidances/ucm126486. htm.
20. N. Schmitz, L. Trümper, M. Ziepert et al., "Treatment and prognosis of mature T-cell and NK-cell lymphoma: An analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group, " Blood, vol. 116, no. 18, pp. 3418-3425, 2010.
21. H. M. Kantarjian, S. O'Brien, T. L. Smith et al., "Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia, " Journal of Clinical Oncology, vol. 18, no. 3, pp. 547-561, 2000.
22. A. Korfel, T. Elter, E. Thiel et al., "Phase II study of central nervous system (CNS)-directed chemotherapy including highdose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas, " Haematologica, vol. 98, no. 3, pp. 364-370, 2013.
23. M. Martelli, J. M. Andrés, C. Agostinelli, A. Di Rocco, M. Pfreundschuh, and S. A. Pileri, "Diffuse large B-cell lymphoma, " Critical Reviews in Oncology/Hematology, vol. 87, no. 2, pp. 146-171, 2013.
24. C. Gisselbrecht, B. Glass, N. Mounier et al., "Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era, " Journal of Clinical Oncology, vol. 28, no. 27, pp. 4184-4190, 2010.
25. J.-M. Sancho, J.-M. Ribera, M.-J. Romero, V. Martín-Reina, P. Giraldo, and E. Ruiz, "Compassionate use of intrathecal depot liposomal cytarabine as treatment of central nervous system involvement in acute leukemia: report of 6 cases, " Haematologica, vol. 91, no. 3, article ECR02, 2006.
26. S. D. Baker, R. L. Heideman, W. R. Crom, J. F. Kuttesch, A. Gajjar, and C. F. Stewart, "Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous systemtumors, " Cancer Chemotherapy and Pharmacology, vol. 37, no. 3, pp. 195-202, 1995.
27. A. Younes, H. A. Preti, F. B. Hagemeister et al., "Paclitaxel plus topotecan treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma, " Annals of Oncology, vol. 12, no. 7, pp. 923-927, 2001.
28. T. Philip, C. Guglielmi, A. Hagenbeek et al., "Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma, " The New England Journal of Medicine, vol. 333, no. 23, pp. 1540-1545, 1995.
29. University of Washington, "Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating PatientsWith Relapsed or Refractory Hodgkin Lymphoma (BV-ICE) NCT02227199".
30. S. Heidegger, A. Beer, E. Geissinger et al., "Combination therapy with brentuximab vedotin and cisplatin/cytarabine in a patient with primarily refractory anaplastic lymphoma kinase positive anaplastic large cell lymphoma, " OncoTargets andTherapy, vol. 7, pp. 1123-1127, 2014.